인사이트
Insights From Our Experts
Articles
Employ an Integrated Market Access Strategy to Deliver Brand Success
The pharma/life sciences pipeline is vibrant, with ongoing innovation bringing new hope to patients and providers across many therapeutic areas. Against the backdrop of rapid scientific advancement in and precision medicine and targeted therapies in primary…
What EVERSANA’s Growing Abstract Count at ISPOR U.S. Means to the HEOR Industry
EVERSANA’s Value & Evidence (V&E) and Data & Analytics (D&A) team collectively had an impressive 27 abstracts accepted to ISPOR U.S. 2023, showcasing EVERSANA’s ability to cross-solve for clients’ HEOR needs. EVERSANA’s Value & Evidence and…
Peeking Behind the PBM-lead GPO Curtain
‘PBM-lead GPO,’ a Newly Created Term to Describe Large Scale PBM-Owned Rebate Aggregators PBM-led group purchasing organizations (GPOs) are not true group purchasing organizations in scope, nor are they pure rebate aggregators. Rather, PBM-lead GPOs are…
Elevating Field Reimbursement Manager Performance through Insights & Comparative Data
“Elevating Field Reimbursement Managers’ Performance through Customer-based Insights and Comparative Data,” authored by David Frey, Principal, Specialty Consulting, EVERSANA and Lee Ann Steadman, Senior Vice President, Specialty Consulting, EVERSANA explores the evolving role of Field Reimbursement…
Use of Machine Learning to Accurately Size Market Potential and Optimize Sales and Marketing Resources
Machine Learning as a strategic lever in healthcare. Recent advances in Machine Learning (ML) now make it possible for pharmaceutical companies to more accurately identify patient populations, including misdiagnosed patients with rare diseases and other diseases…
Case Study: Optimizing use of Field Reimbursement Managers
Navigating the complexities of insurance coverage can be a time consuming and challenging task. Field Reimbursement Managers (FRMs) were introduced as a way to help healthcare providers address issues or challenges related to securing timely access…
Case Study: Waste Reduction through Packaging Optimization
Pharmaceutical companies are being challenged to develop more effective delivery mechanisms of their therapies in order to reduce the amount of product waste. Recent changes in legislation, including the Waste Reduction Act of 2022 and adoption…
Accelerated Approval Pathways: Manufacturers Left to Grapple With Risk Versus Reward
Oncology and hematology are extremely complex, crowded and chaotic therapeutic areas. With 30% of drug approvals by the FDA occurring in the oncology and hematology space, manufacturers of these high-science brands are often faced with unprecedented…
Understanding the Inflation Reduction Act: Inflation Rebates
Posted by
Brian Abraham , Michael Kurland , Denise Woltemath , Mike Scott , Kevin McDermott on 3월 9, 20233/9/23
Prescription drug manufacturers routinely implement price increases for a variety of reasons that support their business. With the passage of the Inflation Reduction Act late in 2022, Congress added a twist to these price increases. One…
Bringing a CPT Code to Life to Help in the Fight Against Cancer
An interview with Navid Alipour, CEO of CureMatch, and Brian Abraham, Sr. Director, Market Access & Patient Services with EVERSANA On January 1, CureMatch, a leader in precision medicine that has developed a unique analytical platform…